MedTrace Logo

MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study

NCT03403725 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2021-09-28

Study results available
· View outcomes & findings →

Summary

The purpose of this clinical trial is to identify the highest dose of MEN1309 drug with acceptable safety profile and that can be used in patients affected by CD205-positive solid tumors and Non-Hodgkin Lymphoma

Conditions

  • Metastatic Solid Tumors
  • Relapsed/Refractory Non-Hodgkin Lymphoma

Interventions

DRUG

MEN1309

MEN1309 solution for intravenous infusion once every 3 weeks

Sponsors & Collaborators

  • Menarini Group

    lead INDUSTRY

Principal Investigators

  • Josep Tabernero Head, Medical Oncology Department, MD PhD · Vall d' Hebron Institute of Oncology (VHIO) P. Vall d'Hebron 119-129 08035 Barcelona, Spain

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-28
Primary Completion
2019-10-22
Completion
2020-01-08

Countries

  • Belgium
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03403725 on ClinicalTrials.gov